Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02627976
Other study ID # NL53275.041.15
Secondary ID
Status Completed
Phase N/A
First received December 4, 2015
Last updated January 29, 2018
Start date February 2016
Est. completion date January 2018

Study information

Verified date January 2018
Source UMC Utrecht
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A common complication of breast conserving therapy is breast edema, which may lead to chronic pain, but also reduced quality of life (QoL) and poor cosmetic outcome. When pain is present most patients are currently treated with physical therapy, but evidence of its effectiveness is still low and a gold standard does not yet exist. A downside of physical therapy is that patients have to undergo the therapy regularly and treatment might even has to continue for years after symptoms and treatment started. Another treatment option is a compression vest with the potential, apart from reducing symptoms, to improve self-efficacy in patients because they decide when to wear it without the need to visit therapists. However effectiveness of the compression vest has not yet been objectified in studies.

The aim of this pilot study is to study if there is an effect on pain, QoL and the amount of breast edema of wearing a compression vest, in order to determine whether a large randomized study is feasible.


Description:

In this pilot study, a maximum of 40 patients with symptomatic breast edema after surgery and/or radiotherapy for breast cancer are offered treatment with a compression vest. These patients will be followed for 6 months. Recruitment will continue until 20 active vest users are participating.

Primary endpoint is the course of patient reported pain over a 6 month period. Secondary endpoints are the course of degree of breast edema and quality of life over a 6 month period.

Patients who are wearing the vest may experience relief of breast edema related symptoms. In terms of burden, they might experience a tight feeling on the skin while wearing the vest, which could also be the case when treated with compression therapy and taping by a physical therapist. This tight feeling can be overcome by changing the vest to a larger size. All patients will fill out questionnaires upon inclusion, at 2 weeks, and 1, 3 and 6 months. This will take approximately 10-15 minutes per follow-up moment. Patients will have to visit the hospital at baseline and 1, 3 and 6 months after they started wearing the vest (i.e. 25 minute consult with physical examination, photo documentation of the breast and short basic follow-up questions), and it is expected that additional measurements for fitting a new compression vest will need to be taken 2-5 times during participation in the study. Those fitting measurements will be performed at a location as desired by the patient (e.g. UMC Utrecht or at patients' home).


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date January 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Females, aged 18 years and older.

- Patient treated with surgery and/or radiotherapy for breast cancer, with symptomatic breast edema (e.g. pain).

- Visual Analog Scale (VAS) pain score of 3 or more.

Exclusion Criteria:

- Inability to understand the Dutch language.

- Indicated to undergo radiation treatment of the breast/chestwall within the next 6 months.

- Cardiac complaints.

- Pacemaker.

- Port-a-cath.

- Thrombosis of the arm.

- Pulmonary embolism.

- Pulmonary disease.

- Pregnancy.

- Non-breast cancer related lymph edema.

- Clinical depression or anxiety disorder.

Study Design


Intervention

Device:
Compression vest, Thuasne
Wearing a compression 4 days/weel with a minumum of 6 hours per day

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
UMC Utrecht Thuasne

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of wearing a compression vest on patient reported outcome pain Brief Pain Inventory (BPI) for pain questionnaire At baseline
Primary Effect of wearing a compression vest on patient reported outcome pain two weeks after wearing a compression vest Brief Pain Inventory (BPI) for pain questionnaire 2 weeks
Primary Effect of wearing a compression vest on patient reported outcome pain one month after wearing a compression vest Brief Pain Inventory (BPI) for pain questionnaire 1 month
Primary Effect of wearing a compression vest on patient reported outcome pain three months after wearing a compression vest Brief Pain Inventory (BPI) for pain questionnaire 3 months
Primary Effect of wearing a compression vest on patient reported outcome pain six months after wearing a compression vest Brief Pain Inventory (BPI) for pain questionnaire 6 months
Secondary Effect of wearing a compression vest on degree of breast edema (CTCAE score) During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. At baseline
Secondary Effect of wearing a compression vest on degree of breast edema (CTCAE score) During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. At 1 month
Secondary Effect of wearing a compression vest on degree of breast edema (CTCAE score) During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. At 3 months
Secondary Effect of wearing a compression vest on degree of breast edema (CTCAE score) During each study related visit to the hospital CTCAE score (Common Terminology Criteria for Adverse Events version 4.0) will be registered. At 6 months
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-C30 for quality of life and breast edema symptoms At baseline
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-C30 for quality of life and breast edema symptoms At 2 weeks after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-C30 for quality of life and breast edema symptoms At 1 month after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-C30 for quality of life and breast edema symptoms At 3 months after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-C30 for quality of life and breast edema symptoms At 6 months after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-BR23 for quality of life and breast edema symptoms At baseline
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-BR23 for quality of life and breast edema symptoms At 2 weeks after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-BR23 for quality of life and breast edema symptoms At 1 month after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-BR23 for quality of life and breast edema symptoms At 3 months after wearing a compression vest
Secondary Effect of wearing a compression vest on patient reported quality of life EORTC QLQ-BR23 for quality of life and breast edema symptoms At 6 months after wearing a compression vest
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A